Ved afslutningen af den gensidige anerkendelsesprocedure var der uoverensstemmelse mellem medlemsstaterne om, hvordan den foreslåede indikation skulle affattes for passende at afspejle resultaterne af ASCOT- LLA - og CARDS- forsøgene, så at behandling af ikke- diabetikere effektivt udelukkes, og Spanien anmeldte officielt en indbringelse for voldgift til CHMP den 1. december 2005.
At the end of the MRP procedure there was a discrepancy between Member States regarding the wording of the proposed indication that adequately reflects the data of the ASCOT-LLA and CARDS studies, effectively excluding treatment in non-diabetics, and an official referral for arbitration was notified by Spain to the CHMP on 1 December 2005.